IMO there is no ANDA in the Teva divestiture list that would be classified for $ELTP ANDA pipeline as "must have now" category. Perhaps good to have but definitely not essential.
With absolutely no doubt $ELTP's monies and time are focused 100% on SequestOx FDA approval. After that, Nasrat would focus again on "other" parts of the $ELTP NDA/ANDA business model.
The only take that I can conclude from Nasrat Hakim's Teva divestiture actions is that "possibly" the final "arm" for SequestOx FDA approval plan now has Nasrat complete 100% confidence. It is now 16 days since Jul 14 and IMO $ELTP management have "possibly" come to a 100% agreement with the FDA for the final "arm" successful approval conclusion.
If SequestOx won't be approved near term & another study is required that may setback resubmission 7-8 months at best, I would welcome other pursuits. The trial execution will be done via 3rd party. We wouldn't want the company sitting on their laurels just waiting.
News 
Market Data 
Discover 
AI
